NCT05055063View on ClinicalTrials.gov

A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 18, 2022

Primary Completion Date

February 2, 2027

Study Completion Date

February 2, 2027

Conditions
Myeloma
Interventions
DRUG

Belantamab mafodotin

by vein over 30-60 minutes on Day 1 of each 56-day cycle for the first 6 cycles.

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER